ArticleOxford medical case reports2026
Retroperitoneal myxoid liposarcoma in a 3.5-year-old Afghan child: a case report and review of the literature.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxoid liposarcoma is a malignant soft tissue sarcoma of adipocytic origin that predominantly affects adolescents and young adults. It is exceptionally rare in early childhood, with very few reported cases in children under the age of five. We present a rare case of a 3.5-year-old male child who was admitted to our emergency unit with a large abdominal mass. The patient underwent an exploratory laparotomy with complete excision of the mass, achieving negative surgical margins. Histopathological analysis confirmed the diagnosis of well-differentiated myxoid liposarcoma. The patient subsequently received six cycles of postoperative cyclophosphamide chemotherapy, administered at 20-day intervals. Follow-up tomography scan confirmed a favorable outcome with no evidence of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.